

# Breast Cancer<sup>®</sup>

U P D A T E

An Audio Review Journal for Nurses

Management of Breast Cancer in the Adjuvant and Metastatic Settings

**EDITOR**

Neil Love, MD

**FACULTY**

Charles L Vogel, MD

Alisha Stein, RNC, BSN, OCN

G Thomas Budd, MD

Desiree Grogan, RPA-C



## A Continuing Nursing Education Audio Series

### STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and research leaders with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

### PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists and oncology nurses on the diagnosis and treatment of breast cancer.

### EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings.
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings.

### ACCREDITATION STATEMENT

*CNA/ANCC*

This educational activity for 3.2 contact hours is provided by Postgraduate Institute for Medicine (PIM). PIM is an approved provider of continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

*California Board of Registered Nursing*

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485, for 3.2 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.

### HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This book contains a continuing nursing education post-test, and the corresponding website [BreastCancerUpdate.com/Nurses](http://BreastCancerUpdate.com/Nurses) includes links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of September 2006 through September 2007, participants should read the learning objectives and faculty disclosures, listen to the CDs and complete the post-test and evaluation form located in the back of this book or on the [BreastCancerUpdate.com/Nurses](http://BreastCancerUpdate.com/Nurses) website and mail or fax the post-test and evaluation form to Postgraduate Institute for Medicine.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Nurses*, please email us at [Info@ResearchToPractice.net](mailto:Info@ResearchToPractice.net), or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

# Breast Cancer®

U P D A T E

## FACULTY AFFILIATIONS



**Charles L. Vogel, MD**  
Medical Director  
Cancer Research Network Inc  
Plantation, Florida



**G. Thomas Budd, MD**  
Professor of Medicine  
Cleveland Clinic Lerner College  
of Medicine of Case Western  
Reserve University  
Cleveland Clinic Foundation  
Cleveland, Ohio



**Alisha Stein, RNC, BSN, OCN**  
CNS/Research Coordinator  
Cancer Research Network Inc  
Plantation, Florida



**Desiree Grogan, RPA-C**  
Cancer Institute of Long Island  
Great Neck, New York

## CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CNE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CNE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

**Dr Vogel** — Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Cancer International Research Group (BCIRG), Genentech BioOncology, GlaxoSmithKline, Ortho Biotech Products LP, Pfizer Inc, Sanofi-Aventis, Tibotec Inc; **Speakers Bureau:** Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Ortho Biotech Products LP, Pfizer Inc, Pierre-Fabre Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Aventis, Tibotec Inc; **Contracted Research:** Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Cancer International Research Group (BCIRG), Eisai Inc, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, NSABP, Ortho Biotech Products LP, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd, Tibotec Inc. **Ms Stein** — Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Amgen Inc. **Dr Budd** — Consulting Fees: Amgen Inc, Exagen Diagnostics, Pfizer Inc; **Contracted Research:** Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Immunicon Corporation, Johnson & Johnson Pharmaceuticals, Pfizer Inc, Wyeth. **Ms Grogan** — Consulting Fees: Amgen Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CNE activity:

Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

*The following PIM clinical content reviewers, Jan Hixon, RN, Linda Graham, RN and Trace Hutchison, PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.*

*This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc do not recommend the use of any agent outside of the labeled indications.*

*The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology or Genomic Health Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.*

**Breast Cancer Update for Nurses — Issue 3, 2006****QUESTIONS (PLEASE CIRCLE ANSWER):**

1. Aromatase inhibitors can be effective in \_\_\_\_\_ patients with hormone receptor-positive breast cancer.
  - a. Premenopausal
  - b. Postmenopausal
  - c. Both pre- and postmenopausal
2. Patients with node-negative, ER-positive disease and a high recurrence score according to the **Oncotype DX™** assay have been shown to benefit from adjuvant \_\_\_\_\_.
  - a. Fulvestrant
  - b. Anastrozole
  - c. Chemotherapy
  - d. All of the above
3. The **Oncotype DX** assay can be used to determine the risk of distant recurrence at 10 years in tamoxifen-treated patients with node-negative, ER-positive breast cancer.
  - a. True
  - b. False
4. Peter Ravdin's Adjuvant! computer model ([adjuvantonline.com](http://adjuvantonline.com)) allows healthcare professionals to enter patient and tumor characteristics to predict \_\_\_\_\_.
  - a. Risk of recurrence
  - b. Benefit from adjuvant therapy
  - c. Both a and b
5. Clinical trials have reported that adjuvant trastuzumab administered to a patient with HER2-positive breast cancer reduces her risk of recurrence by approximately \_\_\_\_\_.
  - a. 10 percent
  - b. 20 percent
  - c. 50 percent
  - d. 70 percent
  - e. 90 percent
6. **Nab** paclitaxel \_\_\_\_\_ require the use of steroid premedication.
  - a. Does
  - b. Does not
7. The incidence of cardiac toxicity with concurrent adjuvant chemotherapy and trastuzumab is approximately \_\_\_\_\_.
  - a. Zero percent
  - b. Four percent
  - c. 10 percent
  - d. 20 percent
8. In patients with breast cancer, which side effect is most commonly associated with bevacizumab?
  - a. Neutropenia
  - b. Alopecia
  - c. Hypertension
  - d. Mucositis
9. In ECOG trial 2100, comparing paclitaxel with or without bevacizumab in the metastatic setting, the addition of bevacizumab significantly \_\_\_\_\_ the response rate and the duration of progression-free survival.
  - a. Increased
  - b. Decreased
10. In the pivotal trial comparing paclitaxel to **nab** paclitaxel, the patients who received \_\_\_\_\_ had a significantly higher response rate and improved time to disease progression.
  - a. Paclitaxel
  - b. **Nab** paclitaxel
11. Which of the following adverse events occur less frequently with aromatase inhibitors than with tamoxifen?
  - a. Endometrial cancer
  - b. Thromboembolic events
  - c. Fractures
  - d. Both a and b

## EVALUATION FORM

### *Breast Cancer Update for Nurses — Issue 3, 2006*

Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity.

**Please answer the following questions by circling the appropriate rating:**

5 = Outstanding                      4 = Good                      3 = Satisfactory                      2 = Fair                      1 = Poor

#### **EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL**

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists and oncology nurses on the diagnosis and treatment of breast cancer. . . . . 5 4 3 2 1

#### **EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES**

**Upon completion of this activity, participants should be better able to:**

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant and metastatic settings. . . . . 5 4 3 2 1
- Describe the selection and sequencing of endocrine therapy in the adjuvant and metastatic settings . . . . . 5 4 3 2 1
- Describe the risks and benefits of chemotherapeutic agents and regimens in the adjuvant and metastatic settings. . . . . 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse. . . . . 5 4 3 2 1
- Explain the risks and benefits of incorporating biologic agents in the adjuvant and metastatic settings. . . . . 5 4 3 2 1

#### **EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS**

Faculty	Knowledge of subject matter	Effectiveness as an educator
Charles L Vogel, MD	5 4 3 2 1	5 4 3 2 1
Alisha Stein, RNC, BSN, OCN	5 4 3 2 1	5 4 3 2 1
G Thomas Budd, MD	5 4 3 2 1	5 4 3 2 1
Desiree Grogan, RPA-C	5 4 3 2 1	5 4 3 2 1

#### **OVERALL EFFECTIVENESS OF THE ACTIVITY**

- Will assist me in improving patient care. . . . . 5 4 3 2 1  
 Fulfilled my educational needs. . . . . 5 4 3 2 1  
 Avoided commercial bias or influence. . . . . 5 4 3 2 1

#### **IMPACT OF THE ACTIVITY**

**The information presented (check all that apply):**

- Reinforced my current practice/treatment habits.                       Enhanced my current knowledge base.

*Breast Cancer Update for Nurses — Issue 3, 2006*

**IMPACT OF THE ACTIVITY (CONTINUED)**

**Will the information presented cause you to make any changes in your practice?**

- Yes       No

**If yes, please describe any change(s) you plan to make in your practice as a result of this activity:**

.....  
 .....

**How committed are you to making these changes?**

(5 = very committed; 1 = not at all committed)..... 5 4 3 2 1

**FUTURE ACTIVITIES**

**Do you feel future activities on this subject matter are necessary and/or important to your practice?**

- Yes       No

**Please list any other topics that would be of interest to you for future educational activities:**

.....  
 .....

**Additional comments about this activity:**

.....  
 .....

**FOLLOW-UP**

**As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:**

- Yes, I am willing to participate in a follow-up survey.       No, I am not willing to participate in a follow-up survey.

**REQUEST FOR CREDIT — please print clearly**

Name: ..... Degree: .....

Organization: ..... Specialty: .....

Address: .....

City, State, Zip: .....

Telephone: ..... Fax: ..... Email: .....

Signature: ..... Date: .....

**Which of the following audio formats of this program did you use?**

- Audio CDs       Downloaded MP3s from website

**To receive acknowledgment of participation in this activity, please complete the post-test and this evaluation/verification of participation and FAX to: (303) 790-4876 or mail to Postgraduate Institute for Medicine, 367 Inverness Parkway, Suite 225, Englewood, CO 80112. The post-test and evaluation may also be completed on the [BreastCancerUpdate.com/Nurses](http://BreastCancerUpdate.com/Nurses) website.**

# Breast Cancer®

U P D A T E

<b>Editor/CME Director</b>	Neil Love, MD
<b>Associate Editors</b>	Richard Kaderman, PhD Kathryn Ault Ziel, PhD
<b>Writers</b>	Lilliam Sklaver Poltorack, PharmD Douglas Paley
<b>Continuing Education Administrator for Nursing</b>	Sally Bogert, RNC, WHCNP
<b>Content Validation</b>	Margaret Peng Ginelle Suarez Erin Wall
<b>Director, Creative and Copy Editing</b>	Aura Herrmann
<b>Creative Manager</b>	Fernando Rendina
<b>Graphic Designers</b>	Jason Cunniss Shantia Daniel
<b>Senior Production Editor</b>	Alexis Oneca
<b>Managing Production Coordinator</b>	Tere Sosa
<b>Copy Editors</b>	Dave Amber Mary DiNunzio Rosemary Hulce Pat Morrissey/Havlin Carol Peschke Susan Petrone
<b>Production Manager</b>	Patricia Kappes
<b>Audio Production</b>	Frank Cesarano
<b>Technical Services</b>	Arly Ledezma
<b>Web Master</b>	John Ribeiro
<b>Contact Information</b>	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net
<b>For CE Information</b>	Email: CME@ResearchToPractice.net

---

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Breast Cancer<sup>®</sup>

U P D A T E

Copyright © 2006 Research To Practice.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.



Co-sponsored by Postgraduate Institute for Medicine and Research To Practice.

Last review date: September 2006

Release date: September 2006

Expiration date: September 2007

Estimated time to complete: 2 hours, 40 minutes